Talabostat Mesylate: FAP and DPP4 Research Workflows
2026-08-29
Build stronger cancer biology experiments with Talabostat mesylate by pairing DPP4 and FAP inhibition with target validation, cytokine profiling, and tumor–stroma assay design. This workflow also shows how recent protein-stability findings can sharpen assay controls without conflating DPP4/FAP biology with DPP8/9-dependent N-degron pathways.
Partial BACE1 Inhibition and Synaptic Transmission
2026-08-28
Satir et al. show that moderate BACE inhibition can reduce amyloid beta secretion in cultured cortical neurons without measurable impairment of synaptic transmission. The study defines a functional boundary for BACE inhibitor research and supports testing exposure levels that lower amyloid production without producing the network effects associated with stronger inhibition.
PDE-5-Silenced BMSCs in Diabetic Cardiac Fibrosis
2026-08-28
This study shows that bone marrow mesenchymal stem cells with reduced PDE-5 expression counteract high-glucose injury in neonatal rat cardiomyocytes and fibroblasts, with concurrent changes in fibrosis, apoptosis, and cGMP/PKG signaling. Its main innovation is to combine BMSC-based cellular modulation with PDE-5 pathway control, providing a mechanistic framework for studying diabetic cardiomyopathy rather than relying only on direct drug treatment.
Asunaprevir (BMS-650032) HCV Research Workflows
2026-08-27
Asunaprevir (BMS-650032) supports a connected workflow from NS3 protease biochemistry to genotype-aware HCV RNA replication inhibition studies. This guide emphasizes formulation, orthogonal readouts, assay controls, and practical troubleshooting so researchers can distinguish target-specific antiviral activity from delivery or cell-health artifacts.
Betaine Hydrochloride for Assay Workflows
2026-08-27
Betaine hydrochloride offers a water-soluble way to test osmolyte and ionic-environment effects in metabolic enzyme and protease workflows. This practical guide combines fresh-solution handling, concentration screens, orthogonal controls, and inflammation-focused assay design inspired by recent esophageal cancer research.
Tolazoline Workflows for α2-Adrenergic Research
2026-08-26
Tolazoline supports controlled studies of α2-adrenergic receptor signaling, airway tone, and pancreatic β-cell secretion. This practical guide connects concentration selection, receptor-binding assays, and troubleshooting so researchers can distinguish receptor antagonism from ATP-sensitive potassium channel effects.
Streptavidin-FITC for Biotin Tracking
2026-08-26
Streptavidin-FITC converts biotinylated antibodies, nucleic acids, and probes into measurable fluorescent signals across microscopy and flow cytometry. Its strongest applied value is a modular detection step for studying lipid nanoparticle trafficking, endosomal retention, and assay-specific sources of background.
Phosbind Acrylamide for Phosphorylation Analysis
2026-08-25
Phosbind Acrylamide is a phosphate-binding reagent for antibody-free protein phosphorylation analysis by SDS-PAGE. Its MnCl2-dependent gel format is designed to resolve phosphorylation-dependent mobility shifts, especially for proteins in the 30–130 kDa range.
Disulfiram A4015: Reliable Assay Design
2026-08-25
This scenario-driven guide explains how Disulfiram (SKU A4015) can support reproducible cell viability, proliferation, cytotoxicity, proteasome, and apoptosis workflows. It connects formulation, dosing, controls, and interpretation to published evidence while distinguishing practical assay guidance from translational conclusions.
Tolazoline: α2-Adrenergic Antagonist Workflows
2026-08-24
Tolazoline supports mechanism-driven studies of α2-adrenergic receptor signaling, pancreatic β-cell secretion, and airway smooth muscle tone. Its concentration-dependent ATP-sensitive potassium channel activity makes paired receptor and ion-channel controls essential for interpreting results.
Boc-D-FMK for Apoptosis and Inflammation Workflows
2026-08-23
Boc-D-FMK provides a cell-permeable, irreversible pan-caspase blockade for separating caspase-dependent death from inflammatory signaling. This practical guide connects controlled cell assays with renal endothelial inflammation and hepatocyte apoptosis models while showing how to interpret results alongside the CYP2B6 glioblastoma findings.
LL-37 Fragments Against MDR A. baumannii
2026-08-22
The 2013 reference study systematically compared LL-37 and three derived fragments, including KR-12, against multidrug-resistant Acinetobacter baumannii. Its key contribution was showing that rapid bacterial killing, inhibition of surface adherence, and activity against established biofilms are related but distinct peptide effects that should be measured separately.
CCT007093: A Practical PPM1D Inhibitor Workflow
2026-08-21
CCT007093 connects biochemical PPM1D inhibition with measurable P38 kinase activation, cell viability changes, and pyroptosis-associated readouts. This workflow shows how to use the compound in breast cancer and kidney injury models while controlling for DMSO exposure, timing, and pathway-dependent cytotoxicity.
TMAO–PERK Signaling in NAFLD: Study Analysis
2026-08-21
A 2024 Toxicology Letters study used dietary TMAO exposure in zebrafish and complementary liver-cell models to show that TMAO can directly promote steatosis, inflammation, liver injury, and fibrosis alongside PERK-pathway activation. The work strengthens a mechanistic link between a gut microbiota-derived metabolite and NAFLD progression, while also defining experimental opportunities to test whether PERK activation is causally required.
LLY-507: A Practical SMYD2 Inhibitor Workflow
2026-08-20
LLY-507 combines nanomolar biochemical potency with strong selectivity, making it useful for separating SMYD2-dependent signaling from broad methyltransferase effects. This guide translates the compound into reproducible cancer, apoptosis, and renal-fibrosis assay workflows while highlighting the limits of preclinical interpretation.
461 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page